SAN DIEGO, Nov. 2, 2017 /PRNewswire/ — Klotho Therapeutics, Inc. (KTI), a biotechnology company focused on commercializing its patent pending version of the protein/hormone Klotho, announced the first closing of a $10 million Series A Preferred round of financing to advance Klotho development for the highest priority indication: kidney disease. Thynk Capital (thynkcapital.com) led the investment. Proceeds of the financing will fund KTI’s manufacturing scale-up, first in-human studies and Investigational New Drug (IND) application with the FDA.
KTI, a virtual biotech company, has filed patents on modified KLOTHO proteins with great potential to positively impact aging, cognition, kidney function, fibrosis and cancer. KTI is well positioned to enter human trials within 2 years focused on its first indication: acute kidney disease, which kills 300k/year and represents a $2B market opportunity in U.S. alone. Led by successful biotech startup execs, KTI has de-risked the development process to accelerate human proof of concept studies.
Klotho Therapeutics, a virtual biotech developing a kidney disease treatment based on its proprietary engineered version of the human klotho enzyme, said Thursday it has raised $10 million in Series A financing from San Diego’s Thynk Capital.